Video Link: https://www.youtube.com/watch?v=QpjYChm69lc

NeoStem (NYSE MKT: NBS): RedChip Money Report (Air Date Nov. 17, 2012)
NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.From:RedChip Money Report GentryViews:12 0ratingsTime:04:19More inScience Technology

Read this article:
NeoStem (NYSE MKT: NBS): RedChip Money Report (Air Date Nov. 17, 2012) - Video

Comments are closed.